繁體版 / 簡體版
 
R&D PORTFOLIO
/ MS-20(CHEMO YOUNG)

MS-20(CHEMO YOUNG)

Indication
Ameliorating fatique and appetite loss associated with cancer chemotheraphy
Ingredient
Organic soybean and probiotics fermentation products
Dosage
4ml twice daily on an empty stomach, after diluting in 100ml of warm water
Status
Approved by Ministry of Health and Welfare(MOHW):available in Taiwan Market
Mechanism
Immune restoration and regulation
  • MS-20 is a mixture of soybean fermentation metabolites which is produced in strictly controlled fermenter and with carefully chosen microorganisms that mimics human intestinal environment.
  • The manufacturing and R&D procedures of Chemo Young follow the international regulations.
  • MS-20 was approved as new drug by MOHW in 2011.
  • MS-20 acts as an immunemodulator and probiotics to improve immunity and inhibit tumor growth.
  • MS-20 is the first and the only oral medication for ameliorating fatigue and appetite loss in patients receiving chemotherapy and thus improve the quality of life.
  • The estimated market of MS-20 in Taiwan will be around 4.5 billion TWD as every year there will be 90,000 new cancer patients. Worldwide, the number of cancer patients will reach 1.4 millions and the medical needs will be over 20 billion USD every year.

MS-20 has also been shown to be anti-PD-1 booster in mice cancer model by increasing effector cytotoxic T cells and inhibiting tumor growth, reducing myeloid-derived suppressor cells (MDSCs).


体彩p5中奖新闻 宁夏十一选五购买 股票融资融券什么意思 pc蛋蛋幸运28预测群 12262体彩排列3 大盘的股票指数怎么看 快乐10分口诀开奖 群英会今日预测 甘肃十一选五今天开奖 江西快三购买方法 北京快乐8人工计划